Drug Trial Radar · NCT07549386
Efficacy and Safety of Etoricoxib+Diacerein in Osteoarthritis.
Last checked: Nov 20, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
123
Actual
Start
May 24, 2024
Primary completion
Mar 27, 2025
Study completion Oct 15, 2025
Sponsor
- Lead sponsor
- Laboratorios LiomontIndustry
- Sponsor type
- Industry
- Collaborators
- EPIC Research CRO
- First posted
- Apr 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if fixed-dose combination etoricoxib 90 mg + diacerein 50 mg capsule works to treat knee/hip osteoarthritis-associated pain in adults. It will also learn about the safety of the drug. The main questions it aims to answer are: Does etoricoxib+diacerein reduce pain intensity as per WOMAC scale after 60 days? What medical problems do participants have when taking etoricoxib 90 mg+diacerein 50 mg capsule for 60 days? Researchers will compare the test drug etoricoxib 90 mg+diacerein 50 mg capsule to an active comparator (meloxicam 15 mg + diacereina 50 mg) to see if drug ABC works to treat pain in patients with osteoarthritis. Participants will: Take drug the test or comparator drugs every day for 60 days. Visit the clinic once a month for health and outcomes follow-up. Keep a diary of their symptoms, pain intensity, WOMAC scale, adverse events, rescue medication use, other used drugs, and treatment adherence.
Conditions
- Pain Management
- Osteoarthritis
Interventions
Etoricoxib 90 mg + diacerein 50 mgDrug
Once a day for 60 days
Meloxicam 15 mg + diacerein 50 mgDrug
Once a day for 60 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain intensity changeTime frame: At 60 days from baseline
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Grupo Médico ASSET, S.C.
Mexico City, Mexico City, Mexico
RM Pharma Specialists S.A. de C.V.
Mexico City, Mexico City, Mexico
Ainpad, S.C.
Morelia, Michoacán, Mexico
Hospital Centro Quirúrgico Nogalar, S.A. de C.V.
Monterrey, Nuevo León, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.